Neurocognitive Integrity After Proton Therapy for Brain Tumor (PROTON MIND)

September 22, 2026 updated by: European Institute of Oncology

Prospective Evaluation of Neurocognitive Integrity After Proton Therapy for Brain Tumor

Radiation therapy remains a cornerstone in the management of both benign and malignant intracranial tumors, either as monotherapy or combined with surgery and/or chemotherapy. Despite its therapeutic benefits, it is frequently associated with potential long-term adverse effects, with neurotoxicity posing a major challenge, especially in young patients affected by benign primary tumors.

Study Overview

Status

Not yet recruiting

Conditions

Detailed Description

In the brain, late radiotoxicities typically manifest as cognitive dysfunction, leukoencephalopathy, brain atrophy, brain tissue necrosis, cerebrovascular complications, endocrinopathies, and/or secondary malignant neoplasms.

Radiation-induced hippocampal injury, in particular, significantly contributes to cognitive impairment, while broader central nervous system effects arise through multiple mechanisms, including vascular injury, neuronal depletion, chronic inflammation, demyelination, and tissue necrosis.

The severity of cognitive dysfunction depends on multiple factors, including the location and the volume of the tumor, the total radiation dose administered, the fractionation regimen, and the individual susceptibility of the patient, as well as comorbidities (e.g., diabetes, etc.) and concomitant drugs.

The distinct physical characteristics of proton therapy, such as a reduced entrance dose, an eliminated exit dose, and a Bragg peak, provide clear dosimetric advantages over conventional photon treatments. Pencil-beam scanning further improves on earlier passive scattering approaches by delivering modulated proton beamlets for superior target conformality and reduced neutron scatter, thereby limiting low- and intermediate- dose exposure to cranial organs at risk (OARs) while preserving adequate dose coverage within the target volume.

From a radiobiological standpoint, these properties suggest that proton therapy may present a more favorable risk-benefit balance compared to photon-based modalities, particularly for long-term clinical outcomes. It achieves a drastic reduction in the integral dose, offering substantial benefit in decreasing radiation-induced second malignancies, making it mandatory for children when available.

Proton therapy is well established for treating pediatric tumors, CNS tumors such as low-grade gliomas (LGG) and meningiomas, especially if near the optic pathway or brainstem, and all the benign tumors in young patients. In these cases, the primary goal extends beyond curing the disease to preserving neurological and cognitive functions.

Study Type

Observational

Enrollment (Estimated)

60

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Italy
      • Milan, Italy, Italy, 20141
        • European Institute of Oncology, Milan

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients affected by primary central nervous system tumors and eligible for protontherapy as adjuvant or radical treatment

Description

Inclusion Criteria:

  • Primary tumors of Brain Tumor (CNS), benign and malignant
  • Age ≥ 18 years
  • Patients able to speak and read the local language(s) fluently
  • Acceptance and signature of informed consent
  • Radiological diagnosis, biopsy, or previous surgery
  • Concomitant medical therapy is allowed

Exclusion Criteria:

  • Previous brain radiotherapy (any form)
  • High-grade gliomas
  • Patients with concomitant neurological or psychiatric disorders.
  • Pregnancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: PROSPECTIVE

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The presence of cognitive impairment
Time Frame: From the end of Protontherapy through study completion, an average of 1 year.

The primary endpoint will be the presence of cognitive impairment during the first 5 years after enrollment, as measured by a comprehensive neuropsychological assessment.

From the end of Protontherapy through study completion, an average of 1 year.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Perceived cognitive impairment
Time Frame: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.

For Functional Assessment of Cancer Therapy-cognition (FACT-cog) 37 items will be completed (score 1-4)

At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
Depressive symptoms
Time Frame: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.

At Beck Depression Inventory-II (BDI-II) 21 items will be completed (score 0-3)

At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
Anxiety
Time Frame: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.

For State-Trait Anxiety Inventory (STAI) 40 items will be completed (score 1-4)

At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
Quality of Life data (QoL) - EORTC QLQ C30 questionnaires.
Time Frame: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.

For EORTC QLQ C30, 30 items will be completed (score 1-4).

At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
Sleep quality
Time Frame: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.

For Pittsburgh Sleep Quality Index (PSQI) 24 items will be completed (score 0-3)

At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
Cognitive Reserve
Time Frame: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.

For Cognitive Reserve Index questionnaire (CRIq) 20 items will be completed (core 0-1)

At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
Global functioning
Time Frame: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.

For Montreal Cognitive Assessment (MoCA) 30 items will be completed (score 1-5).

At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
Learning and Verbal Memory
Time Frame: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.

For Rey Auditory Verbal Learning Test (RAVLT) 15 items will be completed (score 0-4).

At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
Working memory
Time Frame: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.

For Corsi Span backward/forward 18 items will be completed (score 0-4).

At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
Visual memory
Time Frame: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.

For Rey-Osterrieth complex figure -recall 18 items will be completed (score 0-2).

At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
Visuospatial abilities
Time Frame: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.

For Rey-Osterrieth complex figure -copy 18 items will be completed (score 0-2).

At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
Executive function
Time Frame: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.

For Frontal Assessment Battery (FAB) 30 items will be completed (score 0-3).

At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.
Attention
Time Frame: At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.

For Symbol digit modalities test (SDMT) 110 items will be completed (score 0-1)

At baseline (pre - Protontherapy), 6 and 12 months post-treatment, and then annually for 5 years.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

September 1, 2026

Primary Completion (Estimated)

July 1, 2031

Study Completion (Estimated)

July 1, 2036

Study Registration Dates

First Submitted

September 14, 2026

First Submitted That Met QC Criteria

September 22, 2026

First Posted (Actual)

September 23, 2026

Study Record Updates

Last Update Posted (Actual)

September 23, 2026

Last Update Submitted That Met QC Criteria

September 22, 2026

Last Verified

August 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • UID 5445
  • L2-684 (Other Identifier: Comitato Etico Lombardia 2)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.